Nanospectra Biosciences, Inc.
Nanospectra developing AuroLase™ therapy, a medical device which incorporates a new class of particles to selectively destroy solid tumors. These AuroShell™ particles (also known as nanoshells) are delivered systemically and then activated by a near-infrared laser, resulting in the thermal destruction of the tumor and the blood vessels supplying them without significant damage to healthy tissue. While AuroShell particles can be used to destroy nearly all solid tumors, we plan to conduct our first clinical trial in 2006 in patients with head and neck cancer.
Source: Nanospectra Biosciences, Inc.